Prevention of Bladder Cancer Recurrence
Research on Botanical Formula LCS103
First-of-Its-Kind Solution for NMIBC Care
LCS103 is a patented botanical formula that presents an innovative approach to prevention of bladder cancer recurrence.
In a clinical pilot study, LCS103 showed promising results in reducing recurrence rates in 75%, leading to its progression into Phase 2 clinical trials.
The Unmet Need in Bladder Cancer
Bladder Cancer is
Most common cancer among men in the US
Every Year
New Bladder Cancer Patient Globally
%
Of new cases are Non-Muscle
Invasive Bladder Cancer (NMIBC)
%
Of NMIBC will reccur within
the first 2 years with current treatments
Bladder Cancer: A Global Challenge with High Recurrence and Costs
Prof. Gilad Amiel sheds light on the severity of bladder cancer, the fourth most common cancer in men in the U.S. and a leading global concern. With high recurrence rates and costly treatments, early and effective interventions are critical to improving patient outcomes.
Bladder Cancer Stages & The Focus on NMIBC
Prof. Gilad Amiel explains the three main stages of bladder cancer, highlighting the urgent need for better treatments. With 75% of cases being non-muscle invasive, research efforts are focused on this stage—where innovations like LCS103 could make the biggest impact.
NMIBC: The Lack of Effective Long-Term Solutions
Prof. Gilad Amiel highlights the ongoing challenges in treating non-muscle invasive bladder cancer (NMIBC). Despite available treatments, high recurrence rates, severe side effects, and poor patient adherence reveal a critical gap—there is still no truly effective long-term solution.
LCS103 Clinical Pilot Study Results
75% Reduction
in Bladder Cancer Recurrence
Without LCS103
60% Recurrence
vs.
With LCS103
15% Recurrence
The pilot study included 20 patients who received LCS103 in addition to their conventional treatment. Only 3 patients experienced a recurrence, resulting in a recurrence rate of 15%. This represents a 75% reduction compared to the expected 60% recurrence rate within the first two years.
Symptom Improvement
Additionaly most patients reported reduced urinary symptoms (pain, frequency, urgency, nocturia), less fatigue, and improved overall well-being.
Safety Profile
LCS103 was highly tolerated, with no adverse events reported.
Prof. Gilad Amiel, Chairman of the Urology Department at Rambam Hospital, presents the groundbreaking clinical pilot study on LCS103.
Publication
LCS103 clinical pilot study has been peer-reviewed and published in the Integrative Cancer Therapies Medical Journal.
Click below to learn more:
https://pubmed.ncbi.nlm.nih.gov/38362870/
Phase 2 Clinical Trial of LCS103
Evaluating Efficacy in Reducing Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence
Prof. Gilad Amiel, Chairman of the Urology Department at Rambam Hospital outlines the goals and plan of the upcoming Phase 2 clinical trial of LCS103.
The randomized clinical trial, led by the Urology Department at Rambam Hospital, will include 60 patients with non-muscle-invasive bladder cancer (NMIBC), who will receive LCS103 in combination with their standard treatments for one year.
The primary outcomes will focus on evaluating safety (through adverse events) and the recurrence rate at one year. Secondary outcomes will include stage or grade progression, assessments of inflammatory markers, evaluation of urination symptoms, and overall quality of life.